Reklama
twitter
youtube
facebook
instagram
linkedin
Reklama
Reklama

Milestone Medical, Inc.: Plans of capital raise and uplift to Warsaw Stock Exchange (2014-05-06)

|
selectedselectedselected
Reklama
Aa
Udostępnij
facebook
twitter
linkedin
wykop

RB 11/2014:5-6-2014 Milestone Medical Inc Capital Raise and Uplift to Warsaw Stock Exchange

Firma: MILESTONE
Spis treści:
1. RAPORT BIEŻĄCY
2. PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ


Milestone Medical Inc
U.S. Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: 212-671-1020
European Contact:
Dom Maklerski WDM S.A.
Email: us@wdmcapital.com
Tel: (+48 71) 79 11 555
Milestone Medical Inc. Announces Plans to Uplist
to the Main Market of the Warsaw Stock Exchange
LIVINGSTON, NJ, May 6, 2014 -- Milestone Medical Inc. (WAR: MMD), today announced its Board of Directors has approved plans for a public offering in connection with an uplisting from the NewConnect Market to the Main Market of the Warsaw Stock Exchange. The uplisting, planned for the second half of 2014, is subject to approval of the Company\'s prospectus by the Polish Financial Supervision Authority (FSA). The prospectus is currently being prepared by Milestone Medical and WDM, one of Central and Eastern Europe\'s leading small cap investment banks.
Leonard Osser, CEO of Milestone Medical, said, “We have made significant progress since our initial listing in late 2013, and look forward to transitioning to the Main Market of the Warsaw Stock Exchange, which we believe will help increase awareness and expand the audience of potential investors in Milestone Medical.\"
In connection with the Company\'s prospectus and public offering, the board has authorized the issuance of new shares valued at $6-7 million USD. The shares are expected to be issued at a post-money valuation of at least $92 million USD, or approximately 12 PLN/$3.90 USD per share.
About Milestone Medical Inc.
Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing marketing permission for both instruments in the U.S. and European Union. For more information please visit www.medicalmilestone.com.

Data
Imię i Nazwisko
Stanowisko
Podpis
2014-05-06 15:44:25 Leonard Osser CEO
2014-05-06 15:44:25 Joseph D\'Agostino CFO

Cena akcji Milestone

Cena akcji Milestone w momencie publikacji komunikatu to 6.9 PLN. Sprawdź ile kosztuje akcja Milestone aktualnie.

W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Milestone.

Jesteś dziennikarzem i szukasz pracy? Napisz do nas

Masz lekkie pióro? Interesujesz się gospodarką i finansami? Możliwe, że szukamy właśnie Ciebie.

Zgłoś swoją kandydaturę

Reklama